| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/13/2002 | WO2001079170A3 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
| 06/13/2002 | WO2001078748A3 Immunomodulatory methods using carbohydrate antigens |
| 06/13/2002 | WO2001077057A3 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 06/13/2002 | WO2001076577A3 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| 06/13/2002 | WO2001074839A3 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use |
| 06/13/2002 | WO2001072721A3 Synergistic methods and compositions for treating cancer |
| 06/13/2002 | WO2001072309A3 Treatment of cerebrovascular disease |
| 06/13/2002 | WO2001070233A3 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
| 06/13/2002 | WO2001068828A3 Compositions and methods for regulated protein expression in gut |
| 06/13/2002 | WO2001062237A3 Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| 06/13/2002 | WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 06/13/2002 | WO2001043730A3 The treatment of convulsive states |
| 06/13/2002 | WO2001037819A3 Use of indirubine derivatives for making medicines |
| 06/13/2002 | WO2001035942A3 Analgesic compositions containing buprenorphine |
| 06/13/2002 | WO2001030335A3 Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| 06/13/2002 | WO2001028538A3 Laxative preparation containing l-arginine |
| 06/13/2002 | WO2001010444A3 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 06/13/2002 | WO2001010428A3 Use of n-methyl bases of ethanolamine for prevention of cell death induced by oxidative stress |
| 06/13/2002 | WO2001000199A9 Compounds obtained from salvia species having antiviral activity |
| 06/13/2002 | WO2000037022A3 Combination therapy for the treatment of sepsis |
| 06/13/2002 | WO1999059957A9 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase |
| 06/13/2002 | US20020073428 Downloading and transfer of audio or video data from video broadcasts |
| 06/13/2002 | US20020072798 Muscle tissue engineering |
| 06/13/2002 | US20020072752 Interspinous process implant sizer and distractor with a split head and size indicator and method |
| 06/13/2002 | US20020072735 Multi-step drug dosage forms |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072624 As antiestrogenic and anti-proliferative agent |
| 06/13/2002 | US20020072620 Processes for the purification of tocopherol and/or sterol compounds and compositions containing orthoborate ester mixtures |
| 06/13/2002 | US20020072616 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 06/13/2002 | US20020072615 Useful as intermediate in the preparation of certain small molecules that are useful in therapy or prophylaxis of inflammatory and immune cell-mediated disease |
| 06/13/2002 | US20020072614 For therapy of cardiovascular, cerebrovascular, respiratory and renal disorders |
| 06/13/2002 | US20020072611 Antipsychotic heterocycle compounds |
| 06/13/2002 | US20020072610 Useful as an intermediate in the preparation of certain small molecules that are useful in therapy or prophylaxis of inflammatory and immune cell-mediated diseases |
| 06/13/2002 | US20020072609 Process for preparing arylacetylaminothiazoles |
| 06/13/2002 | US20020072607 Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells |
| 06/13/2002 | US20020072604 For prophylaxis and therapy of obesity, diabetes, sexual disorders, eating disorder; for modulating appetite and metabolic rates; for stimulating appetite of livestock for treatment of ketosis, postpartum anestrus |
| 06/13/2002 | US20020072543 Method for treating tension-type headache |
| 06/13/2002 | US20020072541 Administering active substance selected from creatine, derivatives and combinations thereof in a dosage which reduces or eliminates typical disorders |
| 06/13/2002 | US20020072539 For therapy of tumor necrosis factor(TNF), edema, neurological deficits, stroke and for therapy of pathological conditions caused by TNF-alpha |
| 06/13/2002 | US20020072538 NMDA NR2B antagonists for treatment |
| 06/13/2002 | US20020072537 Comprehensive pharmacologic therapy for treatment of obesity |
| 06/13/2002 | US20020072534 20- Hete antagonists and agonists |
| 06/13/2002 | US20020072533 Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt |
| 06/13/2002 | US20020072531 Useful as anticoagulants in mammals; inhibitors of factor Xa |
| 06/13/2002 | US20020072530 Indole and benzimidazole inhibitors of factor Xa |
| 06/13/2002 | US20020072529 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma |
| 06/13/2002 | US20020072528 Are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit T-helper-type 2 immune response; useful for therapy of viral and neoplastic diseases |
| 06/13/2002 | US20020072526 Orally active salts with tyrosine kinase activity |
| 06/13/2002 | US20020072525 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072524 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072523 For therapy of inflammatory and immune diseases |
| 06/13/2002 | US20020072522 Compositions and methods for the treatment of anorectal disorders |
| 06/13/2002 | US20020072521 For therapy of central nervous system disorders such as stress, anxiety, depression, cardiovascular disorders, and eating disorders |
| 06/13/2002 | US20020072520 For use in therapy of hyperlipidemia and arteriosclerotic disorders |
| 06/13/2002 | US20020072519 Useful as psychotherapeutic agents |
| 06/13/2002 | US20020072518 Bicyclic alphavbeta3 antagonists |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020072513 Process for the production of clavulanic acid salts |
| 06/13/2002 | US20020072512 Method of preventing and treating HIV-mediated central nervous system damage |
| 06/13/2002 | US20020072511 Apparatus and method for delivering compounds to a living organism |
| 06/13/2002 | US20020072510 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 06/13/2002 | US20020072509 Methods for the treatment of a traumatic central nervous system injury |
| 06/13/2002 | US20020072508 For alleviating symptoms associated with depression and mental and emotional stress |
| 06/13/2002 | US20020072505 Such as enprofylline (3-propylxanthine) and MRS 1220; asthma |
| 06/13/2002 | US20020072500 3-(carboxy(hydroxy)alkylaminocarbonylmethylaminocarbonyl), 5-(tetrahydropyrimidin-2-yl-amino)phenol for example |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020072480 Water-soluble, chlorhexidine-containing compositions and use thereof |
| 06/13/2002 | US20020072107 Human osteoclast derived cathepsin |
| 06/13/2002 | US20020072062 Generating clne containing chloramphenicol gene cluster; obtain microgranism, extract genome, form library, transform cells, screen clones for chloramphenicol expression |
| 06/13/2002 | US20020072052 Compositions and methods for regulating bacterial pathogenesis |
| 06/13/2002 | US20020071956 Substrate with a photocatalytic coating |
| 06/13/2002 | US20020071874 Compositions containing therapeutically active components having enhanced solubility |
| 06/13/2002 | US20020071872 Laxative composition |
| 06/13/2002 | US20020071870 Particulates of a water-insoluble pharmaceutical having a solubility of less than 15 mg/ml in an aqueous carrier liquid, then microfluidizing said composition in the presence of at least 0.01% by weight of particulates of a dextrin. |
| 06/13/2002 | US20020071864 Rapidly disintegrable tablet for oral administration |
| 06/13/2002 | US20020071863 Sustained release oral dosage form that is free of in-situ aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug. |
| 06/13/2002 | US20020071861 System for dermal or transdermal application containing an iota-carrageenan and process for its preparation |
| 06/13/2002 | US20020071857 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071837 Preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,OOO MW |
| 06/13/2002 | US20020071832 Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| 06/13/2002 | US20020071829 Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| 06/13/2002 | US20020071816 Contain alph-hydroxytetronic acid or a derivative, and, in some cases, hydroquinone, an alpha -hydroxy acid such as glycolic acid, and a fatty acid ester of ascorbic acid such as ascorbyl palmitate. |
| 06/13/2002 | US20020071815 Antipsoriatic nail polish |
| 06/13/2002 | US20020071812 Contain 1,1,1,2,3,3,3-heptafluoropropane; especially with a betamimetic, an anticholinergic, a steroid, an antiallergic or a PAF-antagonist or a combination of such compounds. |
| 06/13/2002 | US20020071810 Container is provided with a non-metal interior surface so as to reduce chemical degradation |
| 06/13/2002 | US20020071807 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 06/13/2002 | DE10156122A1 Treatment of inflammatory diseases of the ileum and colon comprises administration of phospholipase inhibitors |
| 06/13/2002 | DE10061574A1 Blockierung der Anlagerung von Keimen bei Vögeln Blocking the attachment of germs in birds |
| 06/13/2002 | DE10059864A1 Substituierte Amino-furan-2-yl-essigsäure- und Amino-thien-2-yl-essigsäure-Derivate Substituted amino-furan-2-yl-acetic acid and amino-thien-2-yl-acetic acid derivatives |
| 06/13/2002 | DE10059826A1 Kosmetische, pharmazeutische und dermatologische Mittel Cosmetic, pharmaceutical and dermatological compositions |
| 06/13/2002 | DE10059412A1 Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz Use of 1-phenyl-3-dimethylaminopropane compounds for the therapy of urinary incontinence |
| 06/13/2002 | DE10059411A1 Verwendung von 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for the therapy of urinary incontinence |
| 06/13/2002 | DE10059213A1 Preparing solid composition of poorly soluble compounds, useful e.g. for carotenoid animal feed additives, by flocculating a dispersion with protective colloid |
| 06/13/2002 | DE10051427C1 Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte A method for producing a tetrahydrocannabinol and cannabidiol-containing extract of the cannabis plant material, as well as cannabis extracts |
| 06/13/2002 | DE10049137A1 Production of oily suspensions of water soluble vitamins comprises milling of vitamins in oil or dry milling and suspension in oil |
| 06/13/2002 | DE10041671C1 Verfahren zur Herstellung von Imidazo[1,2-c][2,3]benzodiazepinen sowie Phenylessigsäureester und Oxazol-Derivate als Zwischenprodukte bei deren Herstellung Benzodiazepines process for the preparation of imidazo [1,2-c] [2,3] oxazole and phenylacetic acid esters and derivatives, as intermediates in the preparation thereof |
| 06/13/2002 | CA2437048A1 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |